BSF Enterprise PLC (GB:BSFA)
LSE:BSFA
Top Page
BSF Enterprise PLC
(LSE:BSFA)
Select Model
Select Model
Rating:47Neutral
Price Target:
2.00 p
▲(5.26% Upside)
Action:ReiteratedDate:04/09/26
The score is held down primarily by weak financial performance—persistent losses, negative gross profit, and ongoing cash burn—despite low debt. Technicals add modest support due to strength versus key shorter-term averages, but near-overbought momentum and a sub-200-day trend temper the outlook. Valuation is constrained by loss-making status and the absence of a dividend.
Positive Factors
Low Leverage
Zero reported debt provides durable financial flexibility versus peers in R&D-intensive biotech. With minimal interest burden the company can prioritize R&D, partnerships, or targeted capital raises rather than servicing debt, reducing solvency risk while it pursues commercialization of cultured-meat technologies.
Negative Factors
Negative Gross Profit
Persistent negative gross profit indicates unit economics are not yet viable — costs exceed product revenue before operating expenses. This structural issue must be resolved via pricing, cost reduction, or tech improvement for margins to scale; otherwise revenue growth alone won't yield sustainable profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Zero reported debt provides durable financial flexibility versus peers in R&D-intensive biotech. With minimal interest burden the company can prioritize R&D, partnerships, or targeted capital raises rather than servicing debt, reducing solvency risk while it pursues commercialization of cultured-meat technologies.
Read all positive factors
BSF Enterprise PLC (BSFA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.59M
Dividend YieldN/A
Average Volume (3M)374.14K
Price to Earnings (P/E)―
Beta (1Y)4.28
Revenue Growth-64.18%
EPS Growth12.05%
CountryUK
Employees15
SectorHealthcare
Sector Strength45
IndustryAsset Management
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding128,374,440
10 Day Avg. Volume343,597
30 Day Avg. Volume374,142
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.46
Price to Sales (P/S)75.11
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BSF Enterprise PLC Business Overview & Revenue Model
Company Description
BSF Enterprise Plc does not have significant operations. It intends to acquire the companies or businesses within marketing and technology sectors. The company was incorporated in 2018 and is based in London, United Kingdom....
How the Company Makes Money
BSF Enterprise PLC generates revenue by leveraging its patented tissue-engineering and cellular agriculture technologies. Its primary revenue streams include the licensing of its technology to food and biotechnology companies, sales of cultured me...
BSF Enterprise PLC Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.84K | 57.82K | 12.94K | 0.00 | 0.00 |
| Gross Profit | -127.47K | -26.64K | -86.55K | -160.50K | 0.00 |
| EBITDA | -1.10M | -1.68M | -1.46M | -905.76K | -58.22K |
| Net Income | -1.11M | -1.67M | -1.50M | -930.04K | -58.43K |
Balance Sheet | |||||
| Total Assets | 3.01M | 3.50M | 5.26M | 4.03M | 401.45K |
| Cash, Cash Equivalents and Short-Term Investments | 149.02K | 637.66K | 2.32M | 1.06M | 359.87K |
| Total Debt | 0.00 | 78.05K | 156.93K | 231.88K | 0.00 |
| Total Liabilities | 289.02K | 305.07K | 401.63K | 449.47K | 36.63K |
| Stockholders Equity | 2.72M | 3.19M | 4.86M | 3.58M | 364.82K |
Cash Flow | |||||
| Free Cash Flow | -1.02M | -1.60M | -1.44M | -677.86K | -85.19K |
| Operating Cash Flow | -1.01M | -1.59M | -1.38M | -667.24K | -85.19K |
| Investing Cash Flow | -9.92K | -12.02K | -64.85K | 1.75K | 0.00 |
| Financing Cash Flow | 529.69K | -78.88K | 2.70M | 1.37M | 0.00 |
BSF Enterprise PLC Technical Analysis
Positive
1.90
Price Trends
1.48
Positive
1.84
Positive
2.13
Negative
Market Momentum
0.09
Negative
64.79
Neutral
60.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BSFA, the sentiment is Positive. The current price of 1.9 is above the 20-day moving average (MA) of 1.04, above the 50-day MA of 1.48, and below the 200-day MA of 2.13, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 64.79 is Neutral, neither overbought nor oversold. The STOCH value of 60.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BSFA.
BSF Enterprise PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £6.30M | -7.39 | -140.34% | ― | ― | ― | |
48 Neutral | £1.26M | -0.99 | -37.63% | ― | -100.66% | 84.15% | |
48 Neutral | £2.24M | 1.25 | 37.98% | ― | ― | ― | |
48 Neutral | £4.61M | -1.85 | -12.33% | ― | ― | ― | |
47 Neutral | £2.59M | -3.56 | -46.41% | ― | -64.18% | 12.05% |
* Healthcare Sector Average
GB:BSFA
BSF Enterprise PLC
2.02
0.65
46.91%
GB:BLU
Blue Star Capital
13.25
8.00
152.38%
GB:TRUE
Braveheart Investment
1.60
-2.40
-60.00%
GB:MFAI
Pires Investments
0.43
-0.45
-51.43%
GB:PRIM
Primorus Investments
3.70
0.20
5.71%
GB:CGO
Contango Holdings Plc
0.93
0.04
4.88%
BSF Enterprise PLC Corporate Events
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Showcases World’s First Handbag Made from Cultivated T-Rex Leather
Positive
Apr 7, 2026
BSF Enterprise’s Lab-Grown Leather subsidiary has unveiled what it calls the world’s first handbag made from cultivated T-Rex Leather, a biomaterial engineered from reconstructed dinosaur collagen, now on display at the Art Zoo Museum ...
Business Operations and StrategyPrivate Placements and Financing
BSF Enterprise Raises £385,000 in Share Placing and Appoints New Financial Adviser
Positive
Apr 2, 2026
BSF Enterprise PLC has raised £385,000 through a placing of 38,500,000 new ordinary shares at 1p each to a single strategic investor, arranged within existing headroom and accompanied by one-for-one investor warrants exercisable at 1.5p over ...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Debuts World’s First Lab-Grown T-Rex Leather Handbag
Positive
Apr 2, 2026
BSF Enterprise PLC has unveiled what it describes as the world’s first product made from lab-grown T-Rex Leather, a one-of-a-kind luxury handbag created with avant-garde label Enfin Levé and showcased at Amsterdam’s Art Zoo Museum...
Business Operations and Strategy
BSF Enterprise seals five-year City-Mix supply deal with South Korea’s SeaWith
Positive
Mar 19, 2026
BSF Enterprise’s subsidiary 3D Bio-Tissues has signed a five-year commercial supply agreement with South Korean cultivated meat specialist SeaWith to provide its proprietary City-Mix macromolecular crowder. The deal, estimated to be worth ab...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Hits Milestone in Chromium-Free Lab-Grown Luxury Leather
Positive
Mar 17, 2026
BSF Enterprise’s Lab-Grown Leather subsidiary has successfully tanned scaffold-free, cultivated skin into A4-sized sheets in the UK, using a proprietary process that produces a bio-equivalent “Elemental” leather with the look, fe...
Business Operations and StrategyPrivate Placements and Financing
BSF Enterprise Cancels £15m Fundraise but Pursues New Financing Options
Negative
Mar 13, 2026
BSF Enterprise PLC has mutually agreed with its counterparties to terminate a proposed £15m equity fundraise and associated capital reorganisation, unwinding the agreements that underpinned the transaction. A previously announced £300,00...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Hits Key Milestone With Tannable Lab-Grown Leather at A4 Scale
Positive
Mar 10, 2026
BSF Enterprise’s subsidiary Lab-Grown Leather Limited has produced its first fully tanned, scaffold-free A4-sized skin, approaching 2mm thickness, using its Advanced Tissue Engineering Platform. The Elemental product line now demonstrates in...
Business Operations and StrategyShareholder Meetings
BSF Enterprise Wins Strong Shareholder Backing at AGM
Positive
Mar 3, 2026
BSF Enterprise PLC reported that all resolutions at its Annual General Meeting were passed by shareholders via poll, with each motion receiving near-unanimous support. The strong voting outcomes reaffirm the board’s mandate and provide gover...
Business Operations and StrategyPrivate Placements and Financing
BSF Enterprise Delays Timetable for Equity Fundraise and Capital Reorganisation
Negative
Feb 27, 2026
BSF Enterprise PLC, a developer of tissue-engineered products such as lab-grown leather, cultivated meat and corneal repair technologies, focuses on sustainable, scaffold-free solutions that offer alternatives to traditional materials. Its platfor...
Financial DisclosuresRegulatory Filings and Compliance
BSF Enterprise Corrects Reported Annual Net Loss to £1.11m
Negative
Feb 3, 2026
BSF Enterprise PLC has issued a correction to its recently released Annual Report and Consolidated Financial Statements for the year ended 30 September 2025, clarifying that its reported net loss should be £1,113,527 rather than the previousl...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsShareholder Meetings
BSF Enterprise Marks Breakthroughs in Lab-Grown Leather and Corneal Tech as Loss Narrows
Positive
Feb 2, 2026
BSF Enterprise PLC has published its Annual Report and Accounts for the year to 30 September 2025, highlighting significant technical and commercial progress across its core subsidiaries 3D Bio-Tissues, Lab-Grown Leather and Kerato, as well as its...
Business Operations and StrategyProduct-Related Announcements
BSF’s Kerato Secures Québec-Backed Grant to Drive LiQD Cornea Veterinary Trials and North American Launch
Positive
Jan 19, 2026
Kerato Limited, the corneal-focused biotechnology subsidiary of BSF Enterprise PLC, has secured participation as an industrial partner in a CAD 663,000 PSO V2D grant programme awarded by Québec’s Ministry of Economy, Innovation and Ener...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.